Acroscell announced the release of its cystic fibrosis transmembrane conductance regulator (CFTR) which plays a key role in the pathogenesis of CF, and the further clinical treatment.
— Acroscell, the division of Creative Bioarray, has become a global leading provider of preclinical R&D services specialized in but not limited to cardiovascular & neural system physiological/pathophysiological mechanisms with strong scientific support. Recently, Acroscell announced the release of its cystic fibrosis transmembrane conductance regulator (CFTR) which plays a key role in the pathogenesis of CF, and further clinical treatment.
Cystic fibrosis is the most common fatal autosomal recessive disease. It is caused by a gene mutation on autochromosome number 7, which encodes the cystic fibrosis transmembrane transcription regulator (CFTR) protein. Hereditary CF disease can lead to chronic lung infections and deterioration of lung function, which can lead to death. Cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and chloride channel in vertebrates. The function of CFTR, which transmits the CL A cyclic adenosine monophosphate-dependent anion channel-and HCO 3-across the epithelial surface, the disruption of these ion transport processes plays a central role in the pathogenesis of CF.
These findings provide a theoretical basis for pharmacological regulation of ion transport for targeted transport of CFTR or alternative ion channels that can compensate for CFTR dysfunction, and are a promising treatment method. High-throughput screening supports the development of CFTR modulator compounds. Acroscell offers to test the effect of CFTR functional lead compounds on the epithelium, such as Cl-and HCO 3-secretions from primary human epithelial cells, animal small intestine and colon epithelium.
The CFTR channel is involved in a variety of epithelial cell functions, such as the regulation of pH i and cell volume, the secretion and expansion of mucus, development and growth. The CFTR channel has been recognized as a therapeutic target for the treatment of CF and other diseases. Using epithelial cell lines that overexpress CFTR in a novel digital cell imaging that expresses fluorescent dyes, Acroscell provides a detection method to test the effect of lead compounds on CFTR activity in epithelial cell lines and primary human epithelial cells.
“Acroscell has a comprehensive cell bank with a variety of specialized and unique stable cell lines expressing ion channels, which can be immediately applied to a variety of in vitro and in vivo pharmacological studies.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Acroscell provides a variety of standard and customized drug safety and pharmacological testing methods and panels for drug screening and analysis. Our team has extensive drug discovery capabilities, expertise, and proven experience to successfully meet various project goals in terms of delivering high-quality data and on-time performance.”
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Release ID: 88983283